Last reviewed · How we verify
Relapsed or refractory marginal zone lymphoma (MZL) after at least two prior lines of therapy for whom MAb-based therapy has failed
Approved treatments
- Itovebi · Pfizer
Inavolisib is a PI3K inhibitor with degradative activity against PI3Kα.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Relapsed or refractory marginal zone lymphoma (MZL) after at least two prior lines of therapy for whom MAb-based therapy has failed patent landscape — cliff calendar, originator estates, attackable patents
- Relapsed or refractory marginal zone lymphoma (MZL) after at least two prior lines of therapy for whom MAb-based therapy has failed treatment landscape brief
- Relapsed or refractory marginal zone lymphoma (MZL) after at least two prior lines of therapy for whom MAb-based therapy has failed treatment updates RSS
Frequently asked questions about Relapsed or refractory marginal zone lymphoma (MZL) after at least two prior lines of therapy for whom MAb-based therapy has failed
What drugs treat Relapsed or refractory marginal zone lymphoma (MZL) after at least two prior lines of therapy for whom MAb-based therapy has failed?
Tracked treatments include Itovebi.
What is the treatment for Relapsed or refractory marginal zone lymphoma (MZL) after at least two prior lines of therapy for whom MAb-based therapy has failed?
Standard treatment for Relapsed or refractory marginal zone lymphoma (MZL) after at least two prior lines of therapy for whom MAb-based therapy has failed includes Itovebi. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Relapsed or refractory marginal zone lymphoma (MZL) after at least two prior lines of therapy for whom MAb-based therapy has failed patent cliff · Relapsed or refractory marginal zone lymphoma (MZL) after at least two prior lines of therapy for whom MAb-based therapy has failed CI report
- Treatment: Itovebi · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing